BioSpace News Archive

Drug Development

Untangling the Amyloid-Tau Connection to Inform New Drug Development

Recent data from the Phase III study of donanemab emphasize a correlation between amyloid and tau. Experts say a greater understanding of this link could further Alzheimer’s drug development.

July 13, 2023
·
5 min read
·
Heather McKenzie
Policy

What Does the End of the Student Loan Pause Mean for Biopharma Workers?

For over three years, no interest has accrued on federal student loans and no payments were required. Soon, mandatory payments will resume, leaving workers with less money in the bank.

July 13, 2023
·
2 min read
·
Shawna Williams
Interview Red Flags: 5 Signs of a Toxic Workplace

If you’re on the hunt for a new role, here are five things to look out for that may be indicative of a toxic work environment.

July 13, 2023
·
3 min read
·
Rosemary Scott
FDA

Perrigo’s Opill Gets FDA Approval as First OTC Oral Contraceptive in US

The regulator on Thursday approved Opill, the first oral contraceptive available in the U.S. without a prescription. Perrigo shares rose 6% in response to the news.

July 13, 2023
·
2 min read
·
Rosemary Scott
Policy

Merck Calls for Summary Judgment in IRA Drug Price Negotiation Case

Following its initial lawsuit last month, Merck has now requested that a federal judge rule on its Inflation Reduction Act case against the Biden administration without a trial.

July 13, 2023
·
2 min read
·
Tristan Manalac
Drug Development

FDA Action Alert: Verrica, Citius and Daiichi Sankyo

After beginning July with a splash in the Alzheimer’s space, the FDA is expected to make three decisions during the next two weeks; two for cancer and one for a viral skin disease.

July 13, 2023
·
4 min read
·
Tristan Manalac
Drug Development

Roche’s Ocrevus Subcutaneous Injection Matches IV Infusion in Phase III MS Trial

Data from the OCARINA II trial shows that a 10-minute subcutaneous injection of Ocrevus achieves similar pharmacokinetics as the typical hours-long intravenous infusion in multiple sclerosis patients.

July 13, 2023
·
2 min read
·
Tristan Manalac
Business

Harbour BioMed Announces 2023 Interim Results Positive Profit Alert with the Enhancement of Value Driven by Innovation

Harbour BioMed announces that, it is anticipated that the Company will record a significant increase in its revenue for the six months ended June 30, 2023, leading to profitable results and notable achievements in cost reduction and efficiency improvement.

July 13, 2023
·
5 min read
Lone Star Bio

The Caris Precision Oncology Alliance Welcomes The Broad Institute of MIT and Harvard

Caris Life Sciences®, the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced that the Broad Institute of MIT and Harvard has joined the Caris Precision Oncology Alliance™.

July 13, 2023
·
4 min read
Pharm Country

Henry Schein Enhances Liquidity Position With New $750 Million Credit Facility

Henry Schein, Inc., the world’s largest provider of health care solutions to office-based dental and medical professionals, announced that it has closed on a new $750 million credit facility with a maturity date of July 2026.

July 13, 2023
·
7 min read